Regeneron (REGN) Tops Q1 EPS by 47c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron Reports First Quarter 2020 Financial and Operating Results
May 5, 2020 6:30 AM EDTTARRYTOWN, N.Y., May 5, 2020 /PRNewswire/ --
First quarter 2020 revenues increased 33% to $1.83 billion versus first quarter 2019(4) First quarter EYLEA® U.S. net sales increased 9% to $1.17 billion versus first quarter 2019 First quarter Dupixent® global net sales(2), which are recorded by Sanofi, increased 129% to $855 million versus first quarter 2019 First quarter 2020 GAAP diluted EPS was $5.43 and non-GAAP diluted EPS(1) was $6.60 Libtayo® Phase 3 trial in first-line non-small cell lung cancer stopped early due to positive overall survival benefit with regulatory submissions planned later this year Libtayo showed... More